{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:56:22Z","timestamp":1791338182531,"version":"4.3.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020742","name":"State Key Laboratory of Anti-Infective Drug Development","doi-asserted-by":"publisher","award":["2015DQ780357"],"award-info":[{"award-number":["2015DQ780357"]}],"id":[{"id":"10.13039\/100020742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejmech.2024.116841","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T12:53:21Z","timestamp":1725627201000},"page":"116841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["In silico assessments of the small molecular boron agents to pave the way for artificial intelligence-based boron neutron capture therapy"],"prefix":"10.1016","volume":"279","author":[{"given":"Yingjun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan S.","family":"Hosmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-0629","authenticated-orcid":false,"given":"Yinghuai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116841_bib1","series-title":"Radiotherapy in Cancer Care: Facing the Global Challenge","author":"Rosenblatt","year":"2017"},{"key":"10.1016\/j.ejmech.2024.116841_bib2","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.3390\/curroncol29100622","article-title":"Boron neutron capture therapy: clinical application and research progress","volume":"29","author":"Cheng","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2024.116841_bib3","first-page":"1","article-title":"Biological effects and therapeutic possibilities of neutrons, Am. J. Roentgenol. Radium","volume":"36","author":"Locher","year":"1936","journal-title":"Ther."},{"key":"10.1016\/j.ejmech.2024.116841_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1073\/pnas.26.3.181","article-title":"Some biological effects of nuclear disintegration products on neoplastic tissue","volume":"26","author":"Kruger","year":"1940","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.116841_bib5","series-title":"Frontiers in Boron-Based Medicinal Chemistry","author":"Zhu","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116841_bib6","first-page":"15","article-title":"Clinical results of boron neutron capture therapy","volume":"54","author":"Hatanaka","year":"1990","journal-title":"Basic Life Sci."},{"key":"10.1016\/j.ejmech.2024.116841_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008390-199209000-00005","article-title":"A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine","volume":"2","author":"Ishiwata","year":"1992","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib8","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/life11040330","article-title":"Theranostics in boron neutron capture therapy","volume":"11","author":"Sauerwein","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ejmech.2024.116841_bib9","series-title":"Boron and Gadolinium Neutron Capture Therapy for Cancer Treatment","author":"Hosmane","year":"2012"},{"key":"10.1016\/j.ejmech.2024.116841_bib10","first-page":"35","article-title":"A realistic appraisal of boron neutron capture therapy as a cancer treatment modality","volume":"38","author":"Barth","year":"2018","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejmech.2024.116841_bib11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/med.21964","article-title":"Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment","volume":"43","author":"Coghi","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2024.116841_bib12","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.3390\/cancers15133277","article-title":"Multi-functional boron-delivery agents for boron neutron capture therapy of cancers","volume":"15","author":"Oloo","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2024.116841_bib13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41467-019-09837-z","article-title":"L-amino acid transporter structure and molecular bases for the asymmetry of substrate interaction","volume":"10","author":"Errasti-Murugarren","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2024.116841_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jphs.2022.10.002","article-title":"Targeting L-type amino acid transporter 1 in urological malignancy: current status and future perspective","volume":"150","author":"Pae","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2024.116841_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49009-z","article-title":"L-type amino acid transporter 1 (LAT1\/Lat1)-Utilizing prodrugs can improve the delivery of drugs into neurons, astrocytes and microglia","volume":"9","author":"Huttunen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116841_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/cas.12602","article-title":"Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2","volume":"106","author":"Wongthai","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2024.116841_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/jrr\/rrac077","article-title":"Correlation between the expression of LAT1 in cancer cells and the potential efficacy of boron neutron capture therapy","volume":"64","author":"Watanabe","year":"2023","journal-title":"J. Radiat. Res."},{"issue":"2 Suppl","key":"10.1016\/j.ejmech.2024.116841_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2024.116841_bib19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2005.05.007","article-title":"Nuclear interaction of EGFR and STAT3 in the activation of the iNOS\/NO pathway","volume":"7","author":"Lo","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2024.116841_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermal growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116841_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00182-17","article-title":"Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection","volume":"91","author":"Venkataraman","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2024.116841_bib22","article-title":"Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis","volume":"11","author":"Vagapova","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116841_bib23","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","article-title":"A decade of FDA-approved drugs (2010\u20132019): trends and future directions","volume":"64","author":"Brown","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116841_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/1078-0432.CCR-07-1968","article-title":"Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies","volume":"14","author":"Yang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic CMYC as a strategy directly cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2024.116841_bib26","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","article-title":"c-Myc and cancer metabolism","volume":"18","author":"Miller","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41388-019-1056-3","article-title":"Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics","volume":"39","author":"Sorolla","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116841_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/ijms20010120","article-title":"Therapeutic inhibition of CMYC in Cancer. Structural bases and computer-aided drug discovery approaches","volume":"20","author":"Carabet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116841_bib29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the \u2018undruggable\u2019 cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116841_bib30","series-title":"Research and Development in the Pharmaceutical Industry, Congressional Budget Office (April 2021)","author":"Austin","year":"2021"},{"key":"10.1016\/j.ejmech.2024.116841_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2024.116841_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41573-019-0050-3","article-title":"Rethinking drug design in the artificial intelligence era","volume":"19","author":"Schneider","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116841_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.omtn.2023.02.019","article-title":"Artificial intelligence for drug discovery: resources, methods, and applications","volume":"31","author":"Chen","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2024.116841_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3390\/ph16060891","article-title":"The role of AI in drug discovery: challenges, opportunities, and strategies","volume":"16","author":"Blanco-Gonz\u00e1lez","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2024.116841_bib35","series-title":"FDA No Longer Needs to Require Animal Tests before Human Drug Trials","author":"Wadman","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116841_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: implications for cancer immunotherapy","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2024.116841_bib37","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"issue":"W1","key":"10.1016\/j.ejmech.2024.116841_bib38","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib39","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.1038\/s41598-021-84787-5","article-title":"Pancancer survival analysis of cancer hallmark genes","volume":"11","author":"Nagy","year":"2021","journal-title":"Sci. Rep."},{"issue":"W","key":"10.1016\/j.ejmech.2024.116841_bib40","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"Schneidman-Duhovny","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/1061186X.2020.1817040","article-title":"Active-site molecular docking of nigellidine with nucleocapsid-NSP2-MPro of COVID-19 and to human IL1R-IL6R and strong antioxidant role of Nigella sativa in experimental rats","volume":"30","author":"Maiti","year":"2022","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejmech.2024.116841_bib42","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.3390\/molecules25204697","article-title":"Synthesis, molecular docking, and in vitro boron neutron capture therapy assay of carboranyl sinomenine","volume":"25","author":"Cai","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116841_bib43","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.ijbiomac.2018.03.100","article-title":"Molecular dynamic of curcumin\/chitosan interaction using a computational molecular approach: emphasis on biofilm reduction","volume":"114","author":"Khezri","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2024.116841_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgr.2014.10.002","article-title":"Structural investigation of ginsenoside Rf with PPAR\u03b3 major transcriptional factor of adipogenesis and its impact on adipocyte","volume":"39","author":"Siraj","year":"2015","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib45","first-page":"e74","article-title":"DSSR-enabled innovative schematics of 3D nucleic acid structures with PyMOL","volume":"48","author":"Lu","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116841_bib46","series-title":"BNCT-new Tool for Cancer treatment_Advances of Boron Drugs Developed in the Sunshine Lake Pharm Co., Ltd, the 694th Session: Boron Containing Drugs for Boron Neutron Capture Therapy","author":"Zhang","year":"2021"},{"key":"10.1016\/j.ejmech.2024.116841_bib47","doi-asserted-by":"crossref","first-page":"74362","DOI":"10.18632\/oncotarget.11413","article-title":"Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma","volume":"7","author":"Bossi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.116841_bib48","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1021\/acs.jcim.7b00113","article-title":"Molecular modeling of the interactions between carborane-containing analogs of indomethacin and cyclooxygenase-2","volume":"57","author":"S\u00e1rosi","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.116841_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.712085","article-title":"Recent developments in free energy calculations for drug discovery","volume":"8","author":"King","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2024.116841_bib50","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1021\/cr200038x","article-title":"Carbaboranes as pharmacophores: properities, synthesis, and application strategies","volume":"111","author":"Scholz","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.116841_bib51","series-title":"Bioinformatics for Geneticists","author":"Barnes","year":"2003"},{"key":"10.1016\/j.ejmech.2024.116841_bib52","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/acs.jctc.7b00905","article-title":"Atomic radius and charge parameter uncertainty in biomolecular solvation energy calculations","volume":"14","author":"Yang","year":"2018","journal-title":"J. Chem. Theor. Comput."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424007220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,10]],"date-time":"2024-11-10T20:39:34Z","timestamp":1731271174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424007220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":52,"alternative-id":["S0223523424007220"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116841","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico assessments of the small molecular boron agents to pave the way for artificial intelligence-based boron neutron capture therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116841"}}